Ultragenyx Pharmaceutical Inc. (RARE)
RARE Stock Price Chart
Explore Ultragenyx Pharmaceutical Inc. interactive price chart. Choose custom timeframes to analyze RARE price movements and trends.
RARE Company Profile
Discover essential business fundamentals and corporate details for Ultragenyx Pharmaceutical Inc. (RARE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
31 Jan 2014
Employees
1.29K
Website
https://www.ultragenyx.comCEO
Emil D. Kakkis
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
RARE Financial Timeline
Browse a chronological timeline of Ultragenyx Pharmaceutical Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 11 Feb 2026
Upcoming earnings on 4 Nov 2025
EPS estimate is -$1.23, while revenue estimate is $167.42M.
Earnings released on 5 Aug 2025
EPS came in at -$1.17 surpassing the estimated -$1.27 by +7.87%, while revenue for the quarter reached $166.50M , beating expectations by +0.33%.
Earnings released on 6 May 2025
EPS came in at -$1.57 falling short of the estimated -$1.54 by -1.95%, while revenue for the quarter reached $139.29M , missing expectations by -14.23%.
Earnings released on 13 Feb 2025
EPS came in at -$1.39 falling short of the estimated -$1.32 by -5.30%, while revenue for the quarter reached $164.88M , beating expectations by +3.89%.
Earnings released on 5 Nov 2024
EPS came in at -$1.40 surpassing the estimated -$1.45 by +3.45%, while revenue for the quarter reached $139.49M , missing expectations by -4.81%.
Earnings released on 1 Aug 2024
EPS came in at -$1.52 surpassing the estimated -$1.64 by +7.32%, while revenue for the quarter reached $147.03M , beating expectations by +19.36%.
Earnings released on 2 May 2024
EPS came in at -$2.03 falling short of the estimated -$1.72 by -18.02%, while revenue for the quarter reached $108.83M , missing expectations by -6.19%.
Earnings released on 15 Feb 2024
EPS came in at -$1.52 surpassing the estimated -$1.65 by +7.88%, while revenue for the quarter reached $127.39M , beating expectations by +6.71%.
Earnings released on 2 Nov 2023
EPS came in at -$2.23 falling short of the estimated -$2.08 by -7.21%, while revenue for the quarter reached $98.05M , missing expectations by -10.88%.
Earnings released on 3 Aug 2023
EPS came in at -$2.25 falling short of the estimated -$2.11 by -6.64%, while revenue for the quarter reached $108.31M , beating expectations by +3.35%.
Earnings released on 4 May 2023
EPS came in at -$2.33 falling short of the estimated -$1.97 by -18.27%, while revenue for the quarter reached $100.50M , missing expectations by -4.01%.
Earnings released on 16 Feb 2023
EPS came in at -$2.16 falling short of the estimated -$2.03 by -6.40%, while revenue for the quarter reached $103.35M , missing expectations by -1.68%.
Earnings released on 2 Nov 2022
EPS came in at -$2.43 falling short of the estimated -$2.29 by -6.11%, while revenue for the quarter reached $90.70M , missing expectations by -5.97%.
Earnings released on 28 Jul 2022
EPS came in at -$2.26 falling short of the estimated -$1.72 by -31.40%, while revenue for the quarter reached $89.34M , beating expectations by +1.77%.
Earnings released on 5 May 2022
EPS came in at -$2.19 falling short of the estimated -$1.76 by -24.43%, while revenue for the quarter reached $79.94M , missing expectations by -4.44%.
Earnings released on 10 Feb 2022
EPS came in at -$1.79 falling short of the estimated -$1.32 by -35.61%, while revenue for the quarter reached $83.39M , missing expectations by -0.49%.
Earnings released on 2 Nov 2021
EPS came in at -$1.08 surpassing the estimated -$1.43 by +24.48%, while revenue for the quarter reached $81.65M , missing expectations by -0.89%.
Earnings released on 2 Aug 2021
EPS came in at -$1.45 falling short of the estimated -$1.28 by -13.28%, while revenue for the quarter reached $86.98M , meeting expectations.
Earnings released on 4 May 2021
EPS came in at -$2.03 falling short of the estimated -$1.25 by -62.40%, while revenue for the quarter reached $99.40M , beating expectations by +11.34%.
Earnings released on 11 Feb 2021
EPS came in at -$1.34 falling short of the estimated -$1.06 by -26.42%, while revenue for the quarter reached $91.54M , missing expectations by -59.44%.
Earnings released on 27 Oct 2020
EPS came in at -$1.13 surpassing the estimated -$1.24 by +8.87%, while revenue for the quarter reached $81.47M , missing expectations by -10.32%.
RARE Stock Performance
Access detailed RARE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.